Skip Nav Destination
Issues
The Biology Behind
Featured Articles
Clinical Trials
Molecular Oncology, Markers, Clinical Correlates
Proliferation Potential-Related Protein, an Ideal Esophageal Cancer Antigen for Immunotherapy, Identified Using Complementary DNA Microarray Analysis
Yoshihiro Yoshitake; Tetsuya Nakatsura; Mikio Monji; Satoru Senju; Hidetake Matsuyoshi; Hirotake Tsukamoto; Seiji Hosaka; Hiroyuki Komori; Daiki Fukuma; Yoshiaki Ikuta; Toyomasa Katagiri; Yoichi Furukawa; Hiromi Ito; Masanori Shinohara; Yusuke Nakamura; Yasuharu Nishimura
[18F]Fluoro-2-deoxy-d-glucose Positron Emission Tomography Detects Gastric Carcinoma in an Early Stage in an Asymptomatic E-Cadherin Mutation Carrier
Mariette C. A. van Kouwen; Joost P. H. Drenth; Wim J. G. Oyen; Joyce H. F. M. de Bruin; Marjolijn J. Ligtenberg; J. J. (Han) Bonenkamp; J. Han J. M. van Krieken; Fokko M. Nagengast
Experimental Therapeutics, Preclinical Pharmacology
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting
Pablo Matar; Federico Rojo; Raúl Cassia; Gema Moreno-Bueno; Serena Di Cosimo; José Tabernero; Marta Guzmán; Sonia Rodriguez; Joaquín Arribas; José Palacios; José Baselga
Regular Articles
Clinical Trials
A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties
Samira Syed; Chris Takimoto; Manuel Hidalgo; Jinee Rizzo; John G. Kuhn; Lisa A. Hammond; Garry Schwartz; Anthony Tolcher; Amita Patnaik; S. Gail Eckhardt; Eric K. Rowinsky
Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774): Early Termination Due To Increased Toxicities
Wells A. Messersmith; Daniel A. Laheru; Neil N. Senzer; Ross C. Donehower; Paula Grouleff; Theresa Rogers; Sean K. Kelley; David A. Ramies; Bert L. Lum; Manuel Hidalgo
A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer
Srinivasan Madhusudan; Martin Foster; Sethupathi R. Muthuramalingam; Jeremy P. Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Denis C. Talbot; Trivadi S. Ganesan; Adrian L. Harris
No Long-Term Increase in Sperm Aneuploidy Rates after Anticancer Therapy: Sperm Fluorescence In situ Hybridization Analysis in 26 Patients Treated for Testicular Cancer or Lymphoma
Claire Thomas; Christine Cans; Roberte Pelletier; Christine De Robertis; Mira Hazzouri; Bernard Sele; Sophie Rousseaux; Sylviane Hennebicq
Cancer Biology, Immunology, Cytokines
Research Articles
Molecular Oncology, Markers, Clinical Correlates
NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer
Shoichiro Fujita; Hisashi Wada; Achim A. Jungbluth; Shuichiro Sato; Tetsuya Nakata; Yuji Noguchi; Yuichiro Doki; Masayoshi Yasui; Yurika Sugita; Takushi Yasuda; Masahiko Yano; Toshiro Ono; Yao-Tseng Chen; Masahiko Higashiyama; Sacha Gnjatic; Lloyd J. Old; Eiichi Nakayama; Morito Monden
Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendroglial Neoplasms and Therapeutic Implications
Peter Birner; Matthias Preusser; Ellen Gelpi; Johannes Berger; Brigitte Gatterbauer; Inge M. Ambros; Peter F. Ambros; Till Acker; Karl H. Plate; Adrian L. Harris; Johannes A. Hainfellner
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment
Marco Colleoni; Giuseppe Viale; David Zahrieh; Giancarlo Pruneri; Oreste Gentilini; Paolo Veronesi; Richard D. Gelber; Giuseppe Curigliano; Rosalba Torrisi; Alberto Luini; Mattia Intra; Viviana Galimberti; Giuseppe Renne; Franco Nolè; Giulia Peruzzotti; Aron Goldhirsch
Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid Carcinoma
Min-Han Tan; Carl Morrison; Pengfei Wang; Ximing Yang; Carola J. Haven; Chun Zhang; Ping Zhao; Maria S. Tretiakova; Eeva Korpi-Hyovalti; John R. Burgess; Khee Chee Soo; Wei-Keat Cheah; Brian Cao; James Resau; Hans Morreau; Bin Tean Teh
Experimental Therapeutics, Preclinical Pharmacology
Distribution of 1-(2-Deoxy-2-fluoro-β-d-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts: Rationale for Therapeutic Use and as a Positron Emission Tomography Probe for Thymidylate Synthase
Julie L. Eiseman; Clive Brown-Proctor; Paul E. Kinahan; Jerry M. Collins; Lawrence W. Anderson; Erin Joseph; Deborah R. Hamburger; Su-shu Pan; Chester A. Mathis; Merrill J. Egorin; Raymond W. Klecker
A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells
Håkon Hov; Randi Utne Holt; Torstein Baade Rø; Unn-Merete Fagerli; Henrik Hjorth-Hansen; Vadim Baykov; James G. Christensen; Anders Waage; Anders Sundan; Magne Børset
Ran, a Small GTPase Gene, Encodes Cytotoxic T Lymphocyte (CTL) Epitopes Capable of Inducing HLA-A33–restricted and Tumor-Reactive CTLs in Cancer Patients
Koichi Azuma; Tetsuro Sasada; Hiroko Takedatsu; Hiroki Shomura; Makoto Koga; Yoshiaki Maeda; Akihisa Yao; Tatsuya Hirai; Arimichi Takabayashi; Shigeki Shichijo; Kyogo Itoh
Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis
Xiaoxin Chen; Su Wang; Nan Wu; Sandeep Sood; Peng Wang; Zhe Jin; David G. Beer; Thomas J. Giordano; Yong Lin; Wei-chung J. Shih; Ronald A. Lubet; Chung S. Yang
Inhibition of the Type III Epidermal Growth Factor Receptor Variant Mutant Receptor by Dominant-Negative EGFR-CD533 Enhances Malignant Glioma Cell Radiosensitivity
Guido Lammering; Theodore H. Hewit; Mathew Holmes; Kristoffer Valerie; William Hawkins; Peck-Sun Lin; Ross B. Mikkelsen; Rupert K. Schmidt-Ullrich
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds